Perspectives - Page 24

A to BE (Bioengineered) Compliance with the New USDA Labeling Requirements

In 2018, the United States Department of Agriculture (USDA) Agricultural Marketing Service (AMS) issued the National Bioengineered Food Disclosure Standard (USDA BE) that went into full effect on January 1, 2022.

View Jan 7, 2022

Going Beyond the Obvious: Competitive Planning and Response

Resource

Psychedelic Medicines as Biopharmaceuticals: Not So Far Out

On-Demand Webinar Dec 13, 2021

Fostering Data Generation to Build the Value Story

Whitepaper Dec 9, 2021

The Value of Insights

Whitepaper Nov 30, 2021

Estimating Comparative Effectiveness Using Single-Arm Trials: Overcoming Additional Challenges in the Tumour-Agnostic Space

Here, in the third of our five-paper series, we focus on the difficulties of estimating the comparative effectiveness of tumour-agnostic treatments.

Whitepaper Nov 30, 2021

Cystic Fibrosis Report

Resource

Understanding the Strategy Behind Viral Vector Selection in Ex Vivo and In Vivo Gene Therapies

Case Study Nov 24, 2021

Medical Affairs Unscripted | Gathering, Understanding, and Leveraging Insights with Muriel Siadak, PAC

Podcast Nov 23, 2021

TCR T-cell Therapies: What if Magic Bullets Simply Aren’t Good Enough?

View Nov 19, 2021

Donor-Derived T-Cells vs. iPSC- and Cord-Derived NKs: Allo Not Created Equal

A common question I get from my cancer cell therapy clients at Cello Health BioConsulting is why, despite the lion share of clinical data in support of T-cell therapies, it is NK cell therapy candidates (iPSC- and cord-derived) that seem of late to be capturing so much more enthusiasm from investors and Pharma these days?

View Nov 11, 2021

Next Generation Therapies for Autoimmune and Inflammatory Diseases – Evolution or Revolution?

On-Demand Webinar Nov 10, 2021

Partnering with the Patient to Innovate and Prepare for the Transition to Commercialization

On-Demand Webinar Nov 9, 2021

Rare Disease Appraisal Landscape and Bringing Novel Technologies to Market

On-Demand Webinar Nov 9, 2021

New Social Media Listening (SML) Insights: Patients’ Perspectives in Rare Disease

On-Demand Webinar Nov 9, 2021

Biopharma Innovation in China Showcased at CSCO 2021

Our team participated in the virtual 2021 Chinese Society of Clinical Oncology (CSCO) Annual Meeting in September, and found clear evidence of China’s emergence as a biopharma innovator.

View Oct 28, 2021